相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The negative impact of T cell-mediated rejection on renal allograft survival in the modern era
Christie Rampersad et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2022)
Evaluation of Clazakizumab (Anti-Interleukin-6) in Patients With Treatment-Resistant Chronic Active Antibody-Mediated Rejection of Kidney Allografts
Stanley C. Jordan et al.
KIDNEY INTERNATIONAL REPORTS (2022)
Clinical and Molecular Profiling to Develop a Potential Prediction Model for the Response to Alemtuzumab Therapy for Acute Kidney Transplant Rejection
Daphne M. Hullegie-Peelen et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2022)
Shifting Clinical Trial Endpoints in Kidney Transplantation: The Rise of Composite Endpoints and Machine Learning to Refine Prognostication
Imran J. Anwar et al.
TRANSPLANTATION (2022)
Safety, tolerability, and efficacy of monoclonal CD38 antibody felzartamab in late antibody-mediated renal allograft rejection: study protocol for a phase 2 trial
Katharina A. Mayer et al.
TRIALS (2022)
Allograft Function as Endpoint for Clinical Trials in Kidney Transplantation
Luuk Hilbrands et al.
TRANSPLANT INTERNATIONAL (2022)
CD38 Antibody Daratumumab for the Treatment of Chronic Active Antibody-mediated Kidney Allograft Rejection
Konstantin Doberer et al.
TRANSPLANTATION (2021)
Imlifidase Desensitization in Crossmatch-positive, Highly Sensitized Kidney Transplant Recipients: Results of an International Phase 2 Trial (Highdes)
Stanley C. Jordan et al.
TRANSPLANTATION (2021)
Do anti-IL-6R blockers have a beneficial effect in the treatment of antibody-mediated rejection resistant to standard therapy after kidney transplantation?
Maeva Massat et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2021)
A review of imlifidase in solid organ transplantation
Bonnie E. Lonze
EXPERT OPINION ON BIOLOGICAL THERAPY (2021)
A Randomized Clinical Trial of Anti-IL-6 Antibody Clazakizumab in Late Antibody-Mediated Kidney Transplant Rejection
Konstantin Doberer et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2021)
BLyS neutralization results in selective anti-HLA alloantibody depletion without successful desensitization
Divyansh Agarwal et al.
TRANSPLANT IMMUNOLOGY (2021)
Therapies for Chronic Allograft Rejection
Min Young Kim et al.
FRONTIERS IN PHARMACOLOGY (2021)
HLA Desensitization in Solid Organ Transplantation: Anti-CD38 to Across the Immunological Barriers
Nizar Joher et al.
FRONTIERS IN IMMUNOLOGY (2021)
Long-Term Survival after Kidney Transplantation
Sundaram Hariharan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Isatuximab: A Review of Its Use in Multiple Myeloma
James E. Frampton
TARGETED ONCOLOGY (2021)
Alemtuzumab as Second-Line Treatment for Late Antibody-Mediated Rejection of Transplanted Kidneys
Michiel G. H. Betjes et al.
TRANSPLANTATION PROCEEDINGS (2021)
Emerging New Approaches in Desensitization: Targeted Therapies for HLA Sensitization
Ashley Y. Choi et al.
FRONTIERS IN IMMUNOLOGY (2021)
Costimulation Blockade in Kidney Transplant Recipients
Marieke van der Zwan et al.
DRUGS (2020)
Imlifidase Inhibits HLA Antibody-mediated NK Cell Activation and Antibody-dependent Cell-mediated Cytotoxicity (ADCC) In Vitro
Shili Ge et al.
TRANSPLANTATION (2020)
First-in-human clinical trial to assess pharmacokinetics, pharmacodynamics, safety, and tolerability of iscalimab, an anti-CD40 monoclonal antibody
Pascal Espie et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2020)
The need for novel trial designs, master protocols, and research consortia in transplantation
Mark D. Stegall et al.
CLINICAL TRANSPLANTATION (2020)
B cells in transplant tolerance and rejection: friends or foes?
Robin Schmitz et al.
TRANSPLANT INTERNATIONAL (2020)
The Banff 2019 Kidney Meeting Report (I): Updates on and clarification of criteria for T cell- and antibody-mediated rejection
Alexandre Loupy et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2020)
Early effects of first-line treatment with anti-interleukin-6 receptor antibody tocilizumab for chronic active antibody-mediated rejection in kidney transplantation
Antonio Lavacca et al.
CLINICAL TRANSPLANTATION (2020)
Effect of Optimized Immunosuppression (Including Rituximab) on Anti-Donor Alloresponses in Patients With Chronically Rejecting Renal Allografts
Kin Yee Shiu et al.
FRONTIERS IN IMMUNOLOGY (2020)
An extension of the RITUX-ERAH study, multicenter randomized clinical trial comparing rituximab to placebo in acute antibody-mediated rejection after renal transplantation
Elodie Bailly et al.
TRANSPLANT INTERNATIONAL (2020)
Low-dose alemtuzumab induction in a tailored immunosuppression protocol for sensitized kidney transplant recipients
Martina Guthoff et al.
BMC NEPHROLOGY (2020)
Y MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial
Marc S. Raab et al.
LANCET HAEMATOLOGY (2020)
The regulation and function of CD20: an enigma of B-cell biology and targeted therapy
Gabriela Pavlasova et al.
HAEMATOLOGICA (2020)
Comparison of Alemtuzumab and Anti-thymocyte Globulin Treatment for Acute Kidney Allograft Rejection
Marieke van der Zwan et al.
FRONTIERS IN IMMUNOLOGY (2020)
Indications for Rituximab Use in an Integrated Health Care Delivery System
Thomas Delate et al.
Journal of Managed Care & Specialty Pharmacy (2020)
Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjogren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study
Benjamin A. Fisher et al.
LANCET RHEUMATOLOGY (2020)
Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab
Kioa Lente Wijnsma et al.
CLINICAL PHARMACOKINETICS (2019)
Desensitization and treatment with APRIL/BLyS blockade in rodent kidney transplant model
Natalie M. Bath et al.
PLOS ONE (2019)
Use of Eculizumab for Active Antibody-mediated Rejection That Occurs Early Post-kidney Transplantation: A Consecutive Series of 15 Cases
Ek Khoon Tan et al.
TRANSPLANTATION (2019)
APRIL/BLyS Blockade Reduces Donor-specific Antibodies in Allosensitized Mice
Nancy A. Wilson et al.
TRANSPLANTATION (2019)
Daratumumab in Sensitized Kidney Transplantation: Potentials and Limitations of Experimental and Clinical Use
Jean Kwun et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2019)
Daratumumab for Treatment of Antibody-Mediated Rejection after ABO-Incompatible Kidney Transplantation
Davide Spica et al.
CASE REPORTS IN NEPHROLOGY AND DIALYSIS (2019)
A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection
Farsad Eskandary et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2018)
Safety, immunogenicity, pharmacokinetics, and efficacy of degradation of anti-HLA antibodies by IdeS (imlifidase) in chronic kidney disease patients
Tomas Lorant et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2018)
Characterization of the in vitro and in vivo properties of CFZ533, a blocking and non-depleting anti-CD40 monoclonal antibody
Jacinda Ristov et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2018)
IdeS (Imlifidase): A Novel Agent That Cleaves Human IgG and Permits Successful Kidney Transplantation Across High-strength Donor-specific Antibody
Bonnie E. Lonze et al.
ANNALS OF SURGERY (2018)
Belimumab in kidney transplantation: an experimental medicine, randomised, placebo-controlled phase 2 trial
Gemma D. Banham et al.
LANCET (2018)
Antibody-Mediated Rejection of Solid-Organ Allografts
Alexandre Loupy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Anti-C1s monoclonal antibody BIVV009 in late antibody-mediated kidney allograft rejectionresults from a first-in-patient phase 1 trial
F. Eskandary et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2018)
Treatment of chronic antibody mediated rejection with intravenous immunoglobulins and rituximab: A multicenter, prospective, randomized, double-blind clinical trial
Francesc Moreso et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2018)
Review of the Clinical Pharmacokinetics and Pharmacodynamics of Alemtuzumab and Its Use in Kidney Transplantation
Marieke van der Zwan et al.
CLINICAL PHARMACOKINETICS (2018)
Prospective Analyses of Circulating B Cell Subsets in ABO-Compatible and ABO-Incompatible Kidney Transplant Recipients
H. A. Schlosser et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2017)
Eculizumab Therapy for Chronic Antibody-Mediated Injury in Kidney Transplant Recipients: A Pilot Randomized Controlled Trial
S. Kulkarni et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2017)
Complement Recognition Pathways in Renal Transplantation
Christopher L. Nauser et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2017)
IgG Endopeptidase in Highly Sensitized Patients Undergoing Transplantation
S. C. Jordan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Overexpression of the Cytokine BAFF and Autoimmunity Risk
M. Steri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Proteasome inhibitors: structure and function
Ana T. Nunes et al.
SEMINARS IN ONCOLOGY (2017)
Alemtuzumab dose adjusted for body weight is associated with earlier lymphocyte repletion and less infective episodes in the first year post renal transplantation - a retrospective study
Michelle Willicombe et al.
TRANSPLANT INTERNATIONAL (2017)
Tocilizumab (Actemra)
Martin Sheppard et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2017)
A systematic review of the use of rituximab for the treatment of antibody-mediated renal transplant rejection
Philip S. Macklin et al.
TRANSPLANTATION REVIEWS (2017)
Alemtuzumab: a review of efficacy and risks in the treatment of relapsing remitting multiple sclerosis
Cristina Guarnera et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2017)
Effect of the Anti-C1s Humanized Antibody TNT009 and Its Parental Mouse Variant TNT003 on HLA Antibody-Induced Complement Activation-A Preclinical In Vitro Study
M. Wahrmann et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2017)
Assessment of Tocilizumab (Anti-Interleukin-6 Receptor Monoclonal) as a Potential Treatment for Chronic Antibody-Mediated Rejection and Transplant Glomerulopathy in HLA-Sensitized Renal Allograft Recipients
J. Choi et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2017)
Alemtuzumab Induction and Delayed Acute Rejection in Steroid-Free Simultaneous Pancreas-Kidney Transplant Recipients
Jonna R. Bank et al.
TRANSPLANTATION DIRECT (2017)
Complement inhibition as potential new therapy for antibody-mediated rejection
Farsad Eskandary et al.
TRANSPLANT INTERNATIONAL (2016)
Plasma-Derived C1 Esterase Inhibitor for Acute Antibody-Mediated Rejection Following Kidney Transplantation: Results of a Randomized Double-Blind Placebo-Controlled Pilot Study
R. A. Montgomery et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2016)
Effect of Treatment With Tabalumab, a B Cell-Activating Factor Inhibitor, on Highly Sensitized Patients With End-Stage Renal Disease Awaiting Transplantation
M. A. Mujtaba et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2016)
Inflammation Causes Resistance to Anti-CD20-Mediated B Cell Depletion
L. H. Laws et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2016)
C1 Inhibitor in Acute Antibody-Mediated Rejection Nonresponsive to Conventional Therapy in Kidney Transplant Recipients: A Pilot Study
D. Viglietti et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2016)
Two cases of kidney transplantation-associated thrombotic microangiopathy successfully treated with eculizumab
Takashi Ikeda et al.
NEPHROLOGY (2016)
One-year Results of the Effects of Rituximab on Acute Antibody-Mediated Rejection in Renal Transplantation: RITUX ERAH, a Multicenter Double-blind Randomized Placebo-controlled Trial
Benedicte Sautenet et al.
TRANSPLANTATION (2016)
Dosing Eculizumab for Antibody-Mediated Rejection in Kidney Transplantation: A Case Report
B. Smith et al.
TRANSPLANTATION PROCEEDINGS (2016)
The Efficacy and Safety of Clazakizumab, an Anti-Interleukin-6 Monoclonal Antibody, in a Phase IIb Study of Adults With Active Psoriatic Arthritis
Philip J. Mease et al.
ARTHRITIS & RHEUMATOLOGY (2016)
Neutralizing BAFF/APRIL With Atacicept Prevents Early DSA Formation and AMR Development in T Cell Depletion Induced Nonhuman Primate AMR Model
J. Kwun et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2015)
A Novel, Blocking, Fc-Silent Anti-CD40 Monoclonal Antibody Prolongs Nonhuman Primate Renal Allograft Survival in the Absence of B Cell Depletion
F. Cordoba et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2015)
Impact of Serotherapy on Immune Reconstitution and Survival Outcomes After Stem Cell Transplantations in Children: Thymoglobulin Versus Alemtuzumab
Laura Willemsen et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
The Bacterial Enzyme IdeS Cleaves the IgG-Type of B Cell Receptor (BCR), Abolishes BCR-Mediated Cell Signaling, and Inhibits Memory B Cell Activation
Sofia Jarnum et al.
JOURNAL OF IMMUNOLOGY (2015)
The Complement System and Antibody-Mediated Transplant Rejection
Erik Stites et al.
JOURNAL OF IMMUNOLOGY (2015)
The perfect storm: HLA antibodies, complement, FcγRs, and endothelium in transplant rejection
Kimberly A. Thomas et al.
TRENDS IN MOLECULAR MEDICINE (2015)
A systematic review of the use of rituximab as induction therapy in renal transplantation
Philip S. Macklin et al.
TRANSPLANTATION REVIEWS (2015)
The Efficacy and Safety of Subcutaneous Clazakizumab in Patients With Moderate-to-Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate
Michael E. Weinblatt et al.
ARTHRITIS & RHEUMATOLOGY (2015)
Complete Removal of Extracellular IgG Antibodies in a Randomized Dose-Escalation Phase I Study with the Bacterial Enzyme IdeS - A Novel Therapeutic Opportunity
Lena Winstedt et al.
PLOS ONE (2015)
A Systematic Review of the Use of Rituximab for Desensitization in Renal Transplantation
Philip S. Macklin et al.
TRANSPLANTATION (2014)
Eculizumab and Splenectomy as Salvage Therapy for Severe Antibody-Mediated Rejection After HLA-Incompatible Kidney Transplantation
Babak J. Orandi et al.
TRANSPLANTATION (2014)
Anti-Interleukin 6 Receptor Antibodies Attenuate Antibody Recall Responses in a Mouse Model of Allosensitization
Irene Kim et al.
TRANSPLANTATION (2014)
Antibody-mediated vascular rejection of kidney allografts: a population-based study
Carmen Lefaucheur et al.
LANCET (2013)
Monoclonal anti-interleukin-6 receptor antibody attenuates donor-specific antibody responses in a mouse model of allosensitization
G. Wu et al.
TRANSPLANT IMMUNOLOGY (2013)
Elevated Pretransplantation Soluble BAFF Is Associated With an Increased Risk of Acute Antibody-Mediated Rejection
Gemma Banham et al.
TRANSPLANTATION (2013)
Therapeutic Cleavage of Anti-Aquaporin-4 Autoantibody in Neuromyelitis Optica by an IgG-Selective Proteinase
Lukmanee Tradtrantip et al.
MOLECULAR PHARMACOLOGY (2013)
BAFF and BAFF-R Levels Are Associated With Risk of Long-Term Kidney Graft Dysfunction and Development of Donor-Specific Antibodies
A. Thibault-Espitia et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2012)
Role of complement and NK cells in antibody mediated rejection
Takurin Akiyoshi et al.
HUMAN IMMUNOLOGY (2012)
Eculizumab Treatment of Acute Antibody-Mediated Rejection in Renal Transplantation: Case Reports
F. Gonzalez-Roncero et al.
TRANSPLANTATION PROCEEDINGS (2012)
Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial
Sandra V. Navarra et al.
LANCET (2011)
Mechanisms involved in antibody- and complement-mediated allograft rejection
Barbara A. Wasowska
IMMUNOLOGIC RESEARCH (2010)
Differential B-lymphocyte regulation by CD40 and its viral mimic, latent membrane protein 1
John P. Graham et al.
IMMUNOLOGICAL REVIEWS (2010)
KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary
Bertram L. Kasiske et al.
KIDNEY INTERNATIONAL (2010)
Successful treatment of experimental glomerulonephritis with IdeS and EndoS, IgG-degrading streptococcal enzymes
Rui Yang et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2010)
Mechanisms of Disease: Rejection of the Kidney Allograft.
Brian J. Nankivell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Proteasome Inhibition Causes Apoptosis of Normal Human Plasma Cells Preventing Alloantibody Production
D. K. Perry et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2009)
Eculizumab
Eline A. Dubois et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2009)
C5 Blockade with Conventional Immunosuppression Induces Long-Term Graft Survival in Presensitized Recipients
R. P. Rother et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2008)
Proteolysis of purified IgGs by human and bacterial enzymes in vitro and the detection of specific proteolytic fragments of endogenous IgG in rheumatoid synovial fluid
Mary H. Ryan et al.
MOLECULAR IMMUNOLOGY (2008)
The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis
Kirsten Neubert et al.
NATURE MEDICINE (2008)
IdeS: A Bacterial Proteolytic Enzyme with Therapeutic Potential
Bjorn P. Johansson et al.
PLOS ONE (2008)
Novel fully human Anti-CD40 monoclonal antibody, 4D11, for kidney transplantation in cynomolgus monkeys
Atsushi Imai et al.
TRANSPLANTATION (2007)
Inhibition of terminal complement components in presensitized transplant recipients prevents antibody-mediated rejection leading to long-term graft survival and accommodation
Hao Wang et al.
JOURNAL OF IMMUNOLOGY (2007)
Blocking of experimental arthritis by cleavage of IgG antibodies in vivo
Kutty Selva Nandakumar et al.
ARTHRITIS AND RHEUMATISM (2007)
Graft produced interleukin-6 functions as a danger signal and promotes rejection after transplantation
Yurong Liang et al.
TRANSPLANTATION (2007)
Intravenous gammaglobulin (IVIG): A novel approach to improve transplant rates and outcomes in highly HLA-sensitized patients
SC Jordan et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2006)
Prevention of acute vascular rejection by a functionally blocking anti-C5 monoclonal antibody combined with cyclosporine
H Wang et al.
TRANSPLANTATION (2005)
Monotherapy with the novel human anti-CD154 monoclonal antibody ABI793 in rhesus monkey renal transplantation model
T Kanmaz et al.
TRANSPLANTATION (2004)
Efficacy and safety of ABI793, a novel human antihuman CD154 monoclonal antibody, in cynomolgus monkey renal allotransplantation
W Schuler et al.
TRANSPLANTATION (2004)
Enzymatic characterization of the streptococcal endopeptidase, IdeS, reveals that it is a cysteine protease with strict specificity for IgG cleavage due to exosite binding
B Vincents et al.
BIOCHEMISTRY (2004)
Structure of the streptococcal endopeptidase IdeS, a cysteine proteinase with strict specificity for IgG
K Wenig et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
CD40/CD154 interactions at the interface of tolerance and immunity
SA Quezada et al.
ANNUAL REVIEW OF IMMUNOLOGY (2004)
Anti-CD40 therapy extends renal allograft survival in rhesus macaques
TC Pearson et al.
TRANSPLANTATION (2002)
IdeS, a novel streptococcal cysteine proteinase with unique specificity for immunoglobulin G
U von Pawel-Rammingen et al.
EMBO JOURNAL (2002)
Structural basis of BLyS receptor recognition
DA Oren et al.
NATURE STRUCTURAL BIOLOGY (2002)
An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway
B Schiemann et al.
SCIENCE (2001)
Therapeutic activity of agonistic monoclonal antibodies against CD40 in a chronic autoimmune inflammatory process
C Mauri et al.
NATURE MEDICINE (2000)
TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease
JA Gross et al.
NATURE (2000)
分享论文
